Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Background Somatic mutations of the k-RAS oncogene have been assessed as a
mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine …

Epidemiologic studies have evaluated the association between KRAS mutations and
resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase …

Human epidermal growth factor receptor (HER) 2/neu kinase domain mutations are found in
approximately 1–4% of lung adenocarcinomas with a similar phenotype to tumors with …

Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease.
Current treatment paradigms are shifting from cytotoxic chemotherapies alone to single …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Based on recent bench and clinical research, the treatment of lung cancer has been refined,
with treatments allocated according to histology and specific molecular features. For …

Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) patients
often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop …